Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 800-801, 2007; 10.1373/clinchem.2006.082735
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambert-Messerlian, G.
Right arrow Articles by Canick, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambert-Messerlian, G.
Right arrow Articles by Canick, J.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Current Issues in Laboratory Medicine
(Clinical Chemistry. 2007;53:800-801.)
© 2007 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Very High Inhibin A Concentration Attributed to Heterophilic Antibody Interference

Geralyn Lambert-Messerlian1,a, Christina Bandera2, Elizabeth Eklund1, Andrew Neuhauser3 and Jacob Canick1

1 Departments of Pathology and Laboratory Medicine, and2 Obstetrics and Gynecology, Women and Infants Hospital and, Brown Medical School, Providence, RI
3 Westerly Hospital, Westerly, RI

aAddress correspondence to this author at: Geralyn Lambert-Messerlian, Division of Prenatal and Special Testing, Women and Infants Hospital, 70 Elm Street, 2nd floor, Providence, Rhode Island 02903. Fax 401-276-7882; gmesserl@wihri.org.

The first 20% of the full text of this article appears below.


To the Editor:

Maternal serum screening for Down syndrome is commonly performed in the 2nd trimester using {alpha} fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and inhibin A. Concentrations of each marker are combined with maternal age to calculate a patient-specific risk of fetal Down syndrome. In cases of Down syndrome, inhibin A concentration is, on average, approximately twice as high as in unaffected singleton pregnancies (1). Second trimester maternal serum inhibin A is also increased in twin pregnancies [1.99 multiples of the median (MoM) (1)] and in Turner syndrome with hydrops (3.91 MoM; (2)). Markedly increased inhibin A has been observed in pregnancies with complete hydatidiform mole [4–7 MoM; (3)]. Increased inhibin A may also be seen in nonpregnant women with ovarian cancer (4).

We describe a . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.